News Archives - Page 157 of 743

TuesdayDec 19, 2023 9:00 am

Amid Increase in Urban Rat Control Worries, SenesTech Inc. (NASDAQ: SNES) Marks Growth Trajectory with New Rodent Birth Control Product, $5M Public Offering

A number of U.S. cities are reporting an increase in complaints about more brazen rat populations, prompting officials in New York City and elsewhere to devote greater revenues to control measures While many rodent control efforts involve traps and poisons, Arizona-based SenesTech Inc., is successfully marketing a one-of-a-kind non-lethal alternative that focuses on chemically preventing rats from birthing an astronomical number of pups throughout the year The company recently rolled out a soft bait fertility control product, adding it to its existing liquid product, opening up the vast professional and consumer rodent control market SenesTech also recently closed a public…

TuesdayDec 19, 2023 8:40 am

Amidst a Difficult Real Estate Market, Mountain Top Properties Inc. (MTPP) Capitalizes on the Hamptons’ Property Sectors Relative Resilience

U.S. existing home sales have suffered a precipitous decline, driven lower by higher interest rates and a lack of supply The Hamptons real estate market has remained largely unscathed, with median home sales prices over 65% higher than those achieved in 2019 Mountain Top Properties have looked to capitalize on the seaside enclave’s historic popularity through the launch of its dedicated Mountain Top Capital Fund I In partnership with Joseph Kelley’s On Site Builder Construction, the fund is looking to raise up to $75 million to construct and sell a range of finished, turnkey properties located across Long Island’s East…

MondayDec 18, 2023 10:30 am

How Clene Inc. (NASDAQ: CLNN) CNM-Au8(R) Takes Advantage of Gold Nanocrystals to Target Neurodegenerative Disorders

Clene, a late clinical-stage biopharmaceutical company, creates clean-surfaced, catalytically active nanocrystals that directly modulate biological systems, including the central nervous system, by improving mitochondrial health The company’s lead investigational candidate, CNM-Au8(R), is currently in development as a disease-modifying treatment for people living with specific types of neurodegenerative disorders (“ND”), namely amyotrophic lateral sclerosis (“ALS”), Parkinson’s Disease, and multiple sclerosis (“MS”) Neurodegenerative disorders are characterized by neurodegeneration – the progressive loss of neuron structure, neuronal functions, and finally, the neurons themselves Nanotherapeutics are in development to stop or reverse neurodegeneration using novel approaches to address the mitochondrial deficits and bioenergetic crises…

MondayDec 18, 2023 9:45 am

PaxMedica Inc. (NASDAQ: PXMD) Fireside Chat with CEO Howard Weisman Sheds Light on Company Achievements for ASD Therapy Pipeline

The CDC estimates 1 out of 36 children in the United States have been diagnosed with Autism Spectrum Disorder – with a therapeutic market potential of $3.42 billion by 2030 PaxMedica’s mission is to help eliminate, reduce, or modulate the troublesome aspects of ASD, an unmet medical need in the industry CEO Howard Weisman shared important updates and achievements in the company’s pipeline, financial outlook, and future vision In a 2020 report released by the Centers for Disease Control and Prevention (“CDC”), it was estimated that 1 out of 36 children had been diagnosed with autism spectrum disorder (“ASD”) in…

MondayDec 18, 2023 9:00 am

GEMXX Corp. (GEMZ) Reports Rise in Earnings, Assets, and Income in 2023, Prepares for Further Strategic Growth in Coming Year

GEMXX Corporation is a Las Vegas-based jewelry maker developing its strategic gold metal and ammolite gemstone from a unique mine-to-market product pipeline Gold has enjoyed record high prices during a “roaring 2023” run, and price fluctuations surrounding those highs have failed to deter optimism that demand for the precious metal may remain during the coming year GEMXX is the only publicly traded ammolite gemstone company in the world, and plans to expand its gemstone and jewelry production by 300 percent next year The company reported upbeat earnings and no long-term debt in its recent Q2 financial statement With the close…

FridayDec 15, 2023 9:45 am

SOHM Inc. (SHMN) Releases New Product Line and Expands Manufacturing Operations in Carlsbad, California

SOHM is launching a line of 13 new chewables that offer a range of health benefits and expand the company's preventative care product portfolio The new line will be available online through Amazon.com and the company's direct-to-consumer website and will be showcased at industry conferences in 2024 SOHM is addressing its increased product demand by establishing a new CDMO GMP manufacturing facility in Carlsbad, California The new manufacturing facility is expected to be open by the end of 2023, and shareholders will be updated about its operations during its year-end 2023 report SOHM (OTC: SHMN), a pharmaceutical, nutraceutical, and cosmeceutical…

FridayDec 15, 2023 9:00 am

SuperCom Ltd.’s (NASDAQ: SPCB) New Contract Reaffirms Company’s Commitment to Improving Public Safety and Extends U.S. Expansion

SuperCom recently secured a new contract to deploy its cutting-edge solutions as part of its broader plan to enhance public safety and support rehabilitation efforts in communities across Kentucky The contract reaffirms the company’s commitment to innovation and excellence in the field of electronic monitoring, according to Ordan Trabelsi, SuperCom’s CEO and President It also marks another valuable step in the company’s expansion within the U.S. The contract allows the company to bring its advanced technology to more communities and aid in the crucial work of domestic violence prevention and offender monitoring SuperCom (NASDAQ: SPCB), a leading global provider of…

ThursdayDec 14, 2023 9:45 am

GSMI Talent Acquisition Week To Connect the Best Industry Recruiters and Talents

The Talent Acquisition Week By GSMI is hosting three phenomenal events this week namely the Social Recruiting Strategies Conference, the Talent Sourcing Strategies Summit, and the Employer Branding Strategies Conference, in San Diego. Sourcers, recruiters, talent branders, HR managers & TA leaders, across industry verticals, are all invited to attend this comprehensive event connecting all recruiting sectors on the global spectrum. These events will feature panel discussions, case studies, and practitioner-to-practitioner sessions that attendees can leverage to gain in-depth knowledge about the latest recruiting industry trends, suitable candidates, tools and technology, and more. Learn the intricacies of recruitment marketing and…

ThursdayDec 14, 2023 9:00 am

Sekur Private Data Ltd. (CSE: SKUR) (OTCQB: SWISF) (FRA: GTD0) Releases SekurRelay Enterprise Email Solution for Executives and Management

SekurRelay allows business executives to benefit from Sekur's privacy and security features seamlessly using their existing email while the rest of the employees maintain their existing hosting provider The service provides extra protection to senior employees and government officials against Business Email Compromise attacks Sekur plans to offer SekurRelay worldwide through telecom partners like America Movil in Latin America and new partners in the Middle East Sekur Private Data (CSE: SKUR) (OTCQB: SWISF) (FRA: GTD0), a cybersecurity and internet privacy provider of Swiss-hosted solutions for secure and private communications, recently announced the launch of its SekurRelay Enterprise Email Solution. This…

WednesdayDec 13, 2023 9:45 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Eyes Additional Revenue Opportunities for 2024; Continues to Generate New Data for its DehydraTECH Technology

Lexaria, a global innovator in drug delivery platforms, is projected by Zacks SCR to be valued at $10 a share, up from the current $1.50 for 2024 Zacks SCR projects a 259% YOY revenue growth for 2024 and a 20% growth for 2025, dependent upon the ultimate approval and commercialization of products employing its patented DehydraTECH(TM) technology Lexaria also anticipates FDA approval for its IND application and commence its Phase 1b hypertension clinical trial, all in 2024 Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, has had significant developments in 2023. Most notably, the company has seen…

Site Search

Company Search

Category: News